Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012435 · ClinicalTrials.gov registry record · Phase 3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 703
- Enrollment target
- 20
- Study locations
NCT06012435: Active Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT06012435 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 703 participants, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (121% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06012435, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 703 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Primary Outcome
The time from date of randomization to date of death due to any cause.
Conditions Studied
Interventions
- DRUG sigvotatug vedotin
- DRUG docetaxel
Study Locations (20)
California
- Providence Medical Foundation - Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center - Fullerton
- Providence St. Jude Medical Center - Fullerton
- Cancer and Blood Specialty Clinic - Los Alamitos
- Cancer Blood and Specialty Clinic - Los Alamitos
- Regulatory Management Only: TRIO-US Central Administration - Los Angeles
- Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D. - Los Angeles
- Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D. - Los Angeles
- UCSF Medical Center - Mission Bay - San Francisco
- Sansum Clinic - Santa Barbara
- Sansum Clinic - Solvang
Colorado
- Rocky Mountain Cancer Centers LLP - Aurora
- Rocky Mountain Cancer Centers LLP - Boulder
- Rocky Mountain Cancer Centers LLP - Colorado Springs
- Rocky Mountain Cancer Centers LLP - Colorado Springs
- Rocky Mountain Cancer Centers LLP - Denver
- Rocky Mountain Cancer Centers LLP - Denver
- Rocky Mountain Cancer Centers LLP - Lakewood
- Rocky Mountain Cancer Centers LLP - Littleton
Alaska
- Alaska Oncology and Hematology, LLC - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 703 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2028-03-11 |
| Phase | Phase 3 |
What the registry record for NCT06012435 still lists
NCT06012435 is an interventional study that assigns participants to a tested intervention. The registered 703 participants enrollment target is mid-sized for trials with a published cap, above the 318-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (121% higher).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which sigvotatug vedotin is the first listed.
NCT06012435 names 20 study sites across 3 states, led by California, Colorado, Alaska.
Frequently Asked Questions
What is clinical trial NCT06012435 about?
NCT06012435 is a clinical study titled "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer". This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an an...
What is the current status of trial NCT06012435?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 703 participants. The study started on 2024-02-21. Estimated completion is 2028-03-11.
What conditions does trial NCT06012435 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06012435?
The interventions under investigation include: sigvotatug vedotin (DRUG), docetaxel (DRUG).
Who is sponsoring clinical trial NCT06012435?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06012435 being conducted?
This trial has 20 study locations across Alaska, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06012435's enrollment target sits among peer trials
703 18th of 130 higher than 113 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI